2nd ADC Linker and Conjugation Summit 2024

With linker and conjugate deals dominating the ADC industry and more companies shifting their focus towards the chemistries behind linkers and conjugations, innovations in this space are becoming a key point of differentiation to preserve your competitive edge.

The 2nd ADC Linker and Conjugation Summit will provide a technical dive into the chemistries behind stable linkers, exploring click cleavable ADCs and their potential applications in safety and efficacy, optimizing site-specific conjugation production of homogenous DAR, innovative linker and conjugation chemistries for advanced ADC development and more.

This conference is a must-attend for anyone facing challenges with hydrophobic and hydrophilic linkers, cleavable and non-cleavable linkers, site-specific conjugations, working with novel payloads to improve conjugation stability. Attending this meeting will empower you to overcome these challenges and develop a stable and efficacious ADC.

Upgrade your resources in this space with unmatched quality in the depth of insights and a community of 100+ topic leaders exclusively working on innovating ADC design through improvement in linker and conjugation technologies.

URLs:
Website: https://go.evvnt.com/2404102-0?pid=176 
Brochure: https://go.evvnt.com/2404102-1?pid=176 
Tickets: https://go.evvnt.com/2404102-2?pid=176 

Time: 8:00 AM - 4:00 PM

Prices:
Drug Developer Conference + Pre-Conference Workshop Day: USD 4097.00,
Drug Developer Conference Only: USD 2899.00,
Academic Conference + Pre-Conference Workshop Day: USD 3497.00,
Academic Conference Only: USD 2499.00,
Solution Provider Conference + Pre-Conference Workshop Day: USD 4997.00,
Solution Provider Conference Only: USD 3599.00

Speakers: Alina Chrzastek, Conjugation Scientist, ADC Therapeutics, Gang Yin, Vice President - Research, Sutro Biopharma, Hyun Yong Cho, Chief Scientific Officer and Senior Managing Director, PinotBio, James Italia, Vice President, BrickBio, Jenny Chang, Senior Scientist - Discovery Biotherapeutics and Bioconjugation, Exelixis, Jeremy Paull, Vice President - Development and Regulatory Affairs, Starpharma Ltd., Kyoji Tsuchikama, Associate Professor, University of Texas Health Science Center at Houston, Marc Robillard, Chief Executive Officer and Founder, Tagworks Pharmaceuticals, Meddy El Alaoui, Chief Executive Officer, AbTx, Paul Sauter, Director - Chemistry and Bioconjugation, VERAXA Biotech GmbH, Philipp Spycher, Chief Scientific Officer and Co-Founder, Araris, Qing Zhou, Founder, Chief Executive Officer, Shanghai Escugen Biotechnology Co., Sofia Genta, Managing Director, University Health Network Canada, Yuan Cheng, Director, Amgen